Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement. The deal covers Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies, enabling SignalChem Biotech to incorporate these AI-designed proteins into custom luminescent assay development and protein-fusion services for third-party customers.
This collaboration expands SignalChem's specialized contract research organization (CRO) capabilities and aligns with Sino Biological's broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio's AI-designed proteins, researchers can potentially obtain high-quality discovery candidates more rapidly, addressing complex biological questions with greater efficiency.
Monod Bio's LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies offer versatile tools for developing customized assays and discovery workflows.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized the value of the partnership: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, noted the strategic significance: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
The licensing agreement underscores the growing trend of AI-driven protein design in the life sciences industry. As AI continues to revolutionize drug discovery and diagnostics, partnerships like this one are likely to become more common, enabling broader access to cutting-edge technologies. For Sino Biological, this move enhances its specialized CRO services, potentially attracting customers seeking advanced assay development solutions.
However, the company noted in a disclaimer that the development of this business may be affected by various factors, including changes in market demand, and given its broad product portfolio, the revenue associated with this business is not expected to have a material impact on overall financial performance.
For more information about Sino Biological and its services, visit www.sinobiological.com. For more about Monod Bio, visit monod.bio.
